XTAI
1707
Market cap396mUSD
Oct 08, Last price
85.40TWD
1D
0.59%
1Q
-6.77%
Jan 2017
-54.33%
Name
Grape King Bio Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Grape King Bio Ltd. is a Taiwanese enterprise specializing in the production and distribution of a diverse array of health-focused items, encompassing pharmaceuticals, traditional remedies, nourishing beverages, and dietary supplements. Its market presence spans Taiwan, mainland China, and various international regions. The company engages with customers through multiple operational avenues, including multi-level marketing channels, conventional distribution networks, and a significant original design and equipment manufacturing (ODM/OEM) division. Among its extensive product range are various mushroom mycelium derivatives, notably ganoderma lucidum, agaricus blazei, antrodia cinnamomea, cordyceps sinensis, and coriolus versicolor. Additionally, it formulates and supplies probiotics featuring strains like enterococcus, bifidobacterium, lactobacillus, pediococcus, streptococcus, saccharomyces, and clostridium, alongside a selection of enzyme products. Beyond its own brand, Grape King Bio offers comprehensive contract services, such as original equipment manufacturing (OEM), original design manufacturing (ODM), custom formulation development, dedicated research and development support, and the provision of raw materials. Established in 1969, the firm maintains its corporate headquarters in Taoyuan City, Taiwan.
Key people
Jin-Chu Chen
General Manager-Longtan Science Park Branch · since 2023
Yuan-Tsung Lin
Deputy General Manager-Business Division · since 2017
Duncan Aitken
Chief Sustainability Officer · since 2024
Bing-Jyun Cuei
Chief Legal Officer · since 2017
Jia-Fong Chai
Director · since 2024
Jue-Jia Chang
Director · since 2009
Hsing-Chun Chen
Director · since 2021
Yen-Shiang Huang
Director · since 2018
Chih-Wei Lai
Director · since 2018
Shenglin Tseng
Chairman of the Board, General Manager · since 2020
Mei-Ching Tseng
Director · since 2015
Ting-Ju Chen
Independent Director · since 2024
Jing Ning Chen
Independent Director · since 2021
Pang-Chung Jin
Independent Director · since 2024
Zhiqiong You
Independent Director · since 2024
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||